|
|
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.China |
First Approval Date25 Jul 2006 |
Open Label Extension Study to Investigate Long Term Safety, Tolerability and Efficacy of Tauroursodeoxycholic Acid in Patients With ALS Who Completed the TUDCA-ALS Study
This study will provide extended access to patients and assess longer-term outcomes on patients who have completed the TUDCA-ALS study.
Efficacy and tolerability clinical trial of Lantigen B (A bacterial lysate having immunostimulating activity) in the prophylaxis of respiratory infections, with special reference to patients with allergy to perennial inhalants. Double-blind multicenter, randomized study vs. placebo.
100 Clinical Results associated with Bruschettini Srl
0 Patents (Medical) associated with Bruschettini Srl
100 Deals associated with Bruschettini Srl
100 Translational Medicine associated with Bruschettini Srl